Literature DB >> 21935689

mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells.

Federico Bolognani1, Anne-Isabelle Gallani, Lena Sokol, David S Baskin, Nicole Meisner-Kober.   

Abstract

Regulation of mRNA decay is an important mechanism controlling gene expression. Steady state levels of mRNAs can be markedly altered by changes in the decay rate. The control of mRNA stability depends on sequences in the transcript itself and on RNA-binding proteins that dynamically bind to these sequences. A well characterized sequence motif, which has been shown to be present in many short-lived mRNAs, is the de-stabilizing adenylate/uridylate-rich element (ARE) located at the 3' untranslated region (3'UTR) of mRNAs. HuR is an RNA-binding protein, which binds to AREs and in doing so, increases the half-life and steady state levels of the corresponding mRNA. Using tissue microarray technology, we found that HuR is over-expressed in human gliomas. We also found that there is a change in HuR localization from being solely in the nucleus to being expressed at high levels in the cytosol. Moreover, a positive correlation was found between total HuR levels, cytosolic localization and tumor grade. We also studied the decay rate of several HuR target mRNAs and found that these mRNAs have a slower rate of decay in glioma cell lines than in astrocytes. Finally, we have been able to decrease both the stability and steady state level of these transcripts in glioma cells using an RNA decoy. More importantly, the decoy transfected cells and cells exposed to a HuR inhibitor have reduced cell growth. In addition, pharmacological inhibition of HuR also resulted in glioma cell growth inhibition. In conclusion, our data suggest that post-transcriptional control abnormalities mediated by HuR are necessary to sustain the rapid growth of this devastating type of cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21935689     DOI: 10.1007/s11060-011-0707-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  49 in total

Review 1.  Development of novel targeted therapies in the treatment of malignant glioma.

Authors:  Jeremy N Rich; Darell D Bigner
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

Review 2.  From birth to death: the complex lives of eukaryotic mRNAs.

Authors:  Melissa J Moore
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

3.  Expression of HuR in Merkel cell carcinoma and in normal skin.

Authors:  Virve Koljonen; Tom Böhling; Caj Haglund; Ari Ristimäki
Journal:  J Cutan Pathol       Date:  2008-01       Impact factor: 1.587

4.  Transdifferentiation of chicken embryonic cells into muscle cells by the 3' untranslated region of muscle tropomyosin.

Authors:  T J L'Ecuyer; P C Tompach; E Morris; A B Fulton
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

5.  Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis.

Authors:  J Dalmau; H M Furneaux; R J Gralla; M G Kris; J B Posner
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

6.  Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.

Authors:  M Marderosian; A Sharma; A P Funk; R Vartanian; J Masri; O D Jo; J F Gera
Journal:  Oncogene       Date:  2006-05-15       Impact factor: 9.867

7.  Decoy mRNAs reduce beta-amyloid precursor protein mRNA in neuronal cells.

Authors:  Pamela R Westmark; Hyun C Shin; Cara J Westmark; Syrus R Soltaninassab; Emily K Reinke; James S Malter
Journal:  Neurobiol Aging       Date:  2006-05-02       Impact factor: 4.673

8.  Role of the RNA-binding protein HuR in colon carcinogenesis.

Authors:  Isabel López de Silanes; Jinshui Fan; Xiaoling Yang; Alan B Zonderman; Olga Potapova; Ellen S Pizer; Myriam Gorospe
Journal:  Oncogene       Date:  2003-10-16       Impact factor: 9.867

9.  Inhibition of myogenesis in transgenic mice expressing the human DMPK 3'-UTR.

Authors:  Christopher J Storbeck; Suzana Drmanic; Kate Daniel; James D Waring; Frank R Jirik; David J Parry; Nazim Ahmed; Luc A Sabourin; Joh-E Ikeda; Robert G Korneluk
Journal:  Hum Mol Genet       Date:  2004-01-20       Impact factor: 6.150

10.  Prognostic role of HuR in hereditary breast cancer.

Authors:  Mira Heinonen; Rainer Fagerholm; Kirsimari Aaltonen; Outi Kilpivaara; Kristiina Aittomäki; Carl Blomqvist; Päivi Heikkilä; Caj Haglund; Heli Nevanlinna; Ari Ristimäki
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

View more
  14 in total

1.  Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles.

Authors:  Aisling J O'Loughlin; Imre Mäger; Olivier G de Jong; Miguel A Varela; Raymond M Schiffelers; Samir El Andaloussi; Matthew J A Wood; Pieter Vader
Journal:  Mol Ther       Date:  2017-04-06       Impact factor: 11.454

2.  RNA-Binding Protein Musashi1 Is a Central Regulator of Adhesion Pathways in Glioblastoma.

Authors:  Philip J Uren; Dat T Vo; Patricia Rosa de Araujo; Rebecca Pötschke; Suzanne C Burns; Emad Bahrami-Samani; Mei Qiao; Raquel de Sousa Abreu; Helder I Nakaya; Bruna R Correa; Caspar Kühnöl; Jernej Ule; Jennifer L Martindale; Kotb Abdelmohsen; Myriam Gorospe; Andrew D Smith; Luiz O F Penalva
Journal:  Mol Cell Biol       Date:  2015-06-22       Impact factor: 4.272

3.  The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells.

Authors:  Dat T Vo; Kotb Abdelmohsen; Jennifer L Martindale; Mei Qiao; Kumiko Tominaga; Tarea L Burton; Jonathan A L Gelfond; Andrew J Brenner; Vyomesh Patel; Daniel Trageser; Björn Scheffler; Myriam Gorospe; Luiz O F Penalva
Journal:  Mol Cancer Res       Date:  2012-01       Impact factor: 5.852

4.  Changes in cellular mRNA stability, splicing, and polyadenylation through HuR protein sequestration by a cytoplasmic RNA virus.

Authors:  Michael D Barnhart; Stephanie L Moon; Alexander W Emch; Carol J Wilusz; Jeffrey Wilusz
Journal:  Cell Rep       Date:  2013-11-07       Impact factor: 9.423

5.  The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells.

Authors:  F M S Gurgis; Y T Yeung; M X M Tang; B Heng; M Buckland; A J Ammit; J Haapasalo; H Haapasalo; G J Guillemin; T Grewal; L Munoz
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

Review 6.  Post-transcriptional regulation of cytokine and growth factor signaling in cancer.

Authors:  Irina Vlasova-St Louis; Paul R Bohjanen
Journal:  Cytokine Growth Factor Rev       Date:  2016-12-02       Impact factor: 7.638

7.  Versatility of RNA-Binding Proteins in Cancer.

Authors:  Laurence Wurth
Journal:  Comp Funct Genomics       Date:  2012-05-14

8.  Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors.

Authors:  Natalia Filippova; Xiuhua Yang; Subramaniam Ananthan; Jennifer Calano; Vibha Pathak; Larry Bratton; Rakesh H Vekariya; Sixue Zhang; Edward Ofori; Emily N Hayward; David Namkoong; David K Crossman; Michael R Crowley; Peter H King; James Mobley; Louis B Nabors
Journal:  Cancer Res       Date:  2021-02-18       Impact factor: 13.312

9.  Circular RNA circAGO2 drives cancer progression through facilitating HuR-repressed functions of AGO2-miRNA complexes.

Authors:  Yajun Chen; Feng Yang; Erhu Fang; Wenjing Xiao; Hong Mei; Huanhuan Li; Dan Li; Huajie Song; Jianqun Wang; Mei Hong; Xiaojing Wang; Kai Huang; Liduan Zheng; Qiangsong Tong
Journal:  Cell Death Differ       Date:  2018-10-19       Impact factor: 15.828

10.  miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer.

Authors:  Wijdan Al-Ahmadi; Maha Al-Ghamdi; Norah Al-Souhibani; Khalid S A Khabar
Journal:  J Pathol       Date:  2013-03-21       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.